Supply Chain Visibility Leader FourKites Partners with Gravity Supply Chain Solutions to Provide Real-time, First-Mile Visibility for Global Shipments
10.5.2023 09:00:00 EEST | Business Wire | Press release
Leading supply chain visibility provider FourKites today announced an exclusive partnership with Gravity, maker of an award-winning supply chain management platform for many of the world’s leading shippers and freight forwarders. The partnership will extend the real-time visibility offered by the FourKites® platform to encompass the first mile — from the time an order is placed with a supplier — all the way through to product delivery via a seamless integration with Gravity’s SaaS solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230509006269/en/
Supply Chain Visibility Leader FourKites Partners with Gravity Supply Chain Solutions to Provide Real-time, First-Mile Visibility for Global Shipments (Photo: Business Wire)
The first mile is often the critical link in the supply chain, when raw materials and purchased finished products are shipped from global suppliers to manufacturing and distribution locations. “Last-mile delivery generates a lot of attention and a lot of headlines, and often overshadows the importance of the first mile,” FourKites founder and CEO Mathew Elenjickal says. “If you don’t have sufficient control over your upstream supply chain, everything that comes after the first mile will be less effective.”
Inefficiencies and disruptions in the first mile have significant ramifications on working capital, costs and revenue. Traditionally, companies have attempted to manage the first mile through manual processes, including spreadsheets and phone calls. This cumbersome, disjointed approach results in unpredictability and higher costs. Consequently, shippers lack the visibility to know if they will have sufficient inventory on hand to meet production and/or distribution schedules, and they are unable to collaborate efficiently with their suppliers to ensure material availability and delivery dates.
Gravity’s modern, easy-to-use SaaS solution addresses these issues, offering visibility into and control over the purchase order process — from order creation through changes and fulfillment. This solution will integrate with FourKites’ real-time shipment visibility and order intelligence solutions to ensure that customers have an exception-based, single source of truth for the entire order life cycle. The highly configurable solution, which can be up and running quickly, will provide seamless integration, simpler collaboration and streamlined operations with real-time updates — all in one centralised platform.
“Of any visibility provider on the market, we chose to partner with FourKites because of its deep, trusted relationships with many large Fortune 1000 customers,” said Graham Parker, CEO and founder of Gravity Supply Chain Solutions. “Our partnership will give these brands a seamless, end-to-end picture of their supply chain, so they can react quickly and confidently to any situation. We have been impressed by FourKites’ innovative solutions, its collaborative culture and its impressive track record of delivering value to customers, and we’re thrilled to work together to fortify our efforts and provide a unique offering to the market.”
Founded in 2015, Gravity is headquartered in Singapore, with offices in the United States, the United Kingdom and Hong Kong. The company has rapidly gained traction in the 3PL and freight forwarder space, and counts among its customers the French conglomerate Bolloré SE, Rӧhlig Logistics, Scan Global Logistics and Gebrüder Weiss.
“As FourKites continues to expand into order and inventory management with solutions such as our Order Intelligence Suite, this partnership with Gravity will extend our capabilities even further upstream,” Elenjickal says. “As a result, our customers can be confident that their suppliers will provide the necessary components and parts they expect by the promised date, eliminating the delays, confusion and costs that many people now incorrectly attribute to issues with the last mile.”
About FourKites
Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509006269/en/
Contact information
Scott Johnston
FourKites EMEA PR Director
+31 62 147 8442
scott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
